Vesnarinone

DRUG4 trials

Sponsors

Otsuka America Pharmaceutical

Conditions

HIV InfectionsSarcoma, Kaposi

Phase 1

A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease

CompletedNCT00002337

Otsuka America PharmaceuticalHIV Infections

Target: 56Updated: 2005-06-24

A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

CompletedNCT00002129

Otsuka America PharmaceuticalHIV Infections

Target: 36Updated: 2005-06-24

Phase 2

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

CompletedNCT00002131

Otsuka America PharmaceuticalHIV Infections, Sarcoma, Kaposi

Target: 28Updated: 2005-06-24

Unknown Phase

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

CompletedNCT00002130

Otsuka America PharmaceuticalHIV Infections

Updated: 2005-06-24